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Dennis Douroumis *a,c
Thermomechanical engineering of pharmaceutical salts in the solid state using continuous extrusion pro-
cessing (ssTME) is a new novel manufacturing approach. In the present work, we introduce a paradigm for
the synthesis of ketoconazole – oxalic acid and ciprofloxacin – maleic acid salts by imparting tempera-
ture, shear rate and stress in comparison to liquid assisted grinding (LAG) approach. We demonstrated that
thermomechanical synthesis is advantageous by producing high quality and pure, solvent-free pharma-
ceutical salts by tailoring extrusion processing variables.
1. Introduction
In the last 20 years, the concept of pharmaceutical salt engineer-
ing has attracted tremendous interest. Salts are defined as crystal-
line materials composed of two or more different molecules, typi-
cally drug and salt formers in the same crystal lattice, where the
components in the crystal lattice are in an ionized state and inter-
act via ionic interactions.1 The development of pharmaceutical
salts offers an efficient way to alter the physicochemical pro-
perties of a drug substance (e.g. dissolution rate, intrinsic solubi-
lity, hygroscopicity, melting point) and subsequently, to enhance
bioavailability, stability, and processability.2 Typically, salt for-
mation is the most preferred method for enhancing the pro-
perties of poorly bioavailable API in the pharmaceutical industry,
with over half of the top 200 prescription drugs currently
approved for use in the USA being pharmaceutical salts.3
To accommodate this demand, the pharmaceutical industry
employs a range of salt production processes such as; single
and multiple effect evaporation, solvent recrystallisation
methods, Mechanical Vapor Recompression, solid and liquid
assisted mechanochemical grinding as well as a range of emer-
ging microfluidic based methods.4 However, many of these
processing strategies have a number of reported issues, such
as low yield, incomplete reaction, long processing times and
high waste content.5 Many of these issues are the result of two
significant issues with current methods of salt production,
and that is they are mostly batch production methods and
require a large a solvent component.
One prevalent issue plaguing pharmaceutical salt develop-
ment is the batch production nature associated with most of
the widely used salification methods. Batch manufacture is a
long-standing obstacle in the pharmaceutical industry,
accounting for higher numbers of processing steps, increased
manufacturing costs, lower yields and increased environ-
mental impact when compared to continuous processing.6
One recent perspective found an overall 10.2% reduction in
resource consumption over the process, plant and industrial
level when using continuous methods over batch production,
highlighting the need for a switch to continuous manufactur-
ing to promote sustainability.7
Another common problem plaguing the traditional manu-
facturing methods of salts is that they require solvent addition
to facilitate the process. Though solvents use in salification
has long been seen as a necessary catalyst, it brings with it a
range of issues. Due to the ionic nature of salts, they have a
propensity for solvate formation.8 Solvate formation is an
undesirable by-product in salt processing, as the additional
agent can react with the bulk constituents, potentially causing
uncontrollable changes to the physiochemical properties of
the product, leading to incomplete transformations and low-
purity batches and the creation of more industrial waste.9 This
by-product has been shown as difficult to control, due to the
relative unpredictability of solvate formation across similar
batches.10 Another drawback of organic solvent use in pharma-
ceutical processing is the shear amount of waste that it
accounts for, with it being estimated that solvents account for
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50% of green-house gas emissions from pharmaceutical manu-
facture.11 In addition, the use of organic solvent requires the
implementation of extra waste disposal systems, raises the risk
of environmental hazards and more volatile solvents can
impose increased health and safety considerations. These
issues highlight the need to develop solvent free process’s for
pharmaceutical manufacture, with one retrospective stating
that “The best solvent, is no solvent” and concluding that the
replacement of solvents with greener alternatives is an impor-
tant step on the road to sustainability.12
One alternative to liquid assisted methods is neat (solid
state) mechanochemical grinding, however, with the lack of a
solvent to act as a catalyst during pharmaceutical process, there
is often insufficient energy present to facilitate a complete con-
version from one form to another.12,13 Recently, milling techno-
logies, such as mixer and ball milling, have been highlighted
for their use as a solvent-free method of mechanochemical pro-
cessing, with the shear forces provided by the balls as a way to
introduce more energy to the system without the need of
solvent.14 However, milling technologies still have issues with
their limited scalability and are batch processed, increasing
their environmental impact. Furthermore, solid-state methods
have been shown as slower and display reduced batch purity
when compared to Liquid assisted grinding methods (LAG).15
Recently extrusion processing has seen increased use as an
environmentally friendly, solvent-free, continuous technology
for the synthesis of pharmaceutical products including salts
and cocrystals.16 The application of elevated temperatures
during the extrusion process, in combination with high-shear
mixing via co-rotating twin screws, has been shown to compen-
sate for the lack of a solvent component, producing high-
purity pharmaceutical products through continuous pro-
duction.17 Extrusion processing is gaining attraction as a more
environmentally friendly, scalable and solvent-free approach to
pharmaceutical processing, with its potential for organic syn-
thesis through condensation reactions and cocrystal pro-
duction being widely reported.18
In this study, we introduce a solid-state thermomechanical
extrusion process (ssTME) for the continuous synthesis of two
different pharmaceutical salts with high quality and yield, fast
processing times and complete process control without using
any solvent. It is important to emphasise that the solvent free
synthesis of pharmaceutical products with high throughput is
an attractive alternative for modern manufacturing processes.
Prior to the processing of drug-former pairs and evaluation of
extrusion as a continuous process for the thermomechanical
synthesis of salts, we employed liquid assisted grinding (LAG)
as a conventional process for comparison purposes. LAG has
been used for screening and optimisation of different multi-
component pharmaceutical products in small scale pro-
ductions.19 In order to demonstrate the potential of the system
process, two well studied pharmaceutical salts, ketoconazole–
oxalic acid (KTZ–OA) and ciprofloxacin–maleic acid (CFX–MA)
were selected for processing.
2. Experimental
2.1 Chemicals
All chemicals were purchased from Sigma-Aldrich Company,
Ltd (Gillingham, UK) except Ciprofloxacin, which was obtained
from TCI (Belgium) and was used as received. The ssTME and
LAG processes are discussed below.
2.2 Solid-state thermomechanical extrusion process (ssTME)
KTZ oxalate extrusion was performed on a co-rotating twin
screw extruder Eurolab-16 (Thermo Fisher, Germany). KTZ and
OA (1 : 1.1; molar stoichiometric ratio) were blended together
for 10 minutes in a Turbula TF2 mixer (Basel, Switzerland) to
produce a uniform mix. The blended physical mixture of KTZ
and OA was then added into the feeder of the extruder. In this
study, a number of variable and non-variable processing para-
meters were explored, to find the optimal processing con-
ditions. Salts were extruded along a 16 mm, 25 L/D barrel by
two 15.6 mm co-rotating twin screws with a 0.47m2 L−1 clear-
ance space. Extruder contains 9 separate heating zones, which
were set to variable temperatures during optimisation
(Table 1). Screws configuration consisted of 8 zones, 4 convey-
ing zones and 3 kneading zones and one discharge zone.
There were 22 individual conveying elements used along the
screw profile and 8 kneading elements at 60 and 90° in zone
A, 6 kneading elements at 60 and 90° angles in zone B and 12
kneading elements at 90° in zone C (full screw design is avail-
able in the ESI†). The kneading zones were designed this way
to provide high shear mixing in the initial extruder zones to
encourage interaction. The screw configuration remained con-
Table 1 Process optimization of CFX–MA salt and KTZ OA salt with different ss TME parameters
Formulation Thermal profile (°C) Screw speed (rpm) Feed rate (%) Torque (%) Residence Time (s) Salt purity (%)
CFX–MA F1 100-160-160-160-200-200-200-200-200 50.0 40 ∼10 97.2 10.6
CFX–MA F2 100-160-160-160-160-160-160-160-160 70.0 35 ∼10 69.5 93.0
CFX–MA F3 80-120-120-120-140-140-140-140-140 70.0 35 ∼15 69.5 96.6
CFX–MA F4 80-100-100-130-130-130-100-100-100 50.0 40 ∼20 97.5 99.0
KTZ–OA 50-75-110-175-185-185-185-185-185 50.0 38 ∼15 97.5 100.0
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stant across the different processing conditions. Critical pro-
cessing parameters such as temperature, screw speed and feed
rates were varied across experiments in order to find the
optimal extrusion conditions for the salts and can be seen in
Table 1. No Die was used in his experiment. After ssTME pro-
cessing, extruded samples were collected and further analysed.
For the ciprofloxacin (CFX) maleate extrusion, a physical
mixture of CFX–MA (1 : 1; molar stoichiometric ratio) was
blended, as before, and transferred into the feeder. The
material was fed from a single-screw volumetric feeder
(Brabender Technology, Germany), which was calibrated to
feed into the first feed port in conveying zone 1 at 0.25 kg h−1
(35%) to 0.3 kg h−1 (40%) for CFX–MA and 0.3 kg h−1 (38%)
for KTZ–OA. Extruded materials were collected at discharge
zone and further analysed.
2.3 Liquid assisting grinding (LAG) process
LAG was performed in 25 ml stainless steel jars using an oscil-
latory ball mill (Retsch MM 400, Germany). Each jar contained
one stainless steel ball. Grinding was at a frequency of 19 Hz.
A physical mixture of bulk KTZ and OA (1 : 1.1 molar stoichio-
metric ratio) was grinded together for 30 minutes. A 200 μl per
g solvent mixture of acetone and methanol (1 : 1) was used
during the process. For the case of CFX and MA (1 : 1 molar
stoichiometric ratio), a solvent mixture of water and ethanol
(1 : 1) was used for the grinding process for the same duration
of time. Batches size was 2 g and performed in triplicate.
2.4 Powder X-ray diffraction (PXRD)
PXRD analyses were performed using a D8 Advanced X-ray
diffractometer (Bruker, Germany) where the data were col-
lected in the 2θ range 2–55° at room temperature. EVA phase
analysis (Bruker, Germany) software was used to analyse the
data and compare the peak positions between bulk materials
and processed ones. The structure of KTZ oxalate and CFX
maleate salt was obtained from the Cambridge structural
database (CSD). Rietveld refinements were performed by using
TOPAS V4.2 (Bruker) software.
2.5 Scanning electron microscopy (SEM)
The morphology of extruded products was examined by using
SEM (Hitachi SU8030, Hitachi High-Tech, Japan), operating at
a voltage of 1 kV. A small portion of the sample was placed on
a sample stub and was subject to analysis after coating was
done by chromium for about 3 min.
2.6 Particle size distribution (PSD)
Particle size distribution of salts was determined using a laser
diffraction instrument (Mastersizer 2000, Malvern, UK),
equipped with a dry powder dispersion accessory (Scirocco
2000, Malvern UK) with a controllable airflow set to 2 bar
applied pressure to break apart any agglomerates. Bulk KTZ,
CFX and post extruded samples were placed into a vibratory
tray, set at 50% to continuously control the rate of powder flow
and assist breaking apart agglomerates. Sampling time was set
at 15 s and each sample was measured three times, in continu-
ous sequence to assist the reproducibility of the batches. A
similar procedure was applied for the measurement of particle
size distribution for the liquid assisted grinded (LAG) materials.
2.7 Differential scanning calorimetry (DSC)
Thermal analyses were performed using differential scanning
calorimetry (Mettler Toledo 823e, Greifensee, Switzerland).
Samples were accurately weighed (2–4 mg), placed into alu-
minium pans and heated over a temperature range starting
from 0 °C to 300 °C at a scan rate of 10 °C min−1 under an
atmosphere of nitrogen using a gas flow of 50 ml min−1.
STARe software was used to analyse the data.
2.8 Fourier transform infrared spectroscopy (FTIR)
The IR Spectra of analysed salts was obtained via FTIR
(Spectrum Two, PerkinElmer, UK) recorded in the wavelength
region of 4000–400 cm−1. The FTIR was equipped with
OMINC® software and a diamond universal attenuated total
reflection unit. The samples were placed on the diamond
crystal and a pressure clamp was used to ensure contact
between the samples and crystal. In all cases, background
spectra were subtracted prior to analysis. All spectra were col-
lected as a mean of three scans at a resolution of 4 cm−1.
2.9 Molecular modelling
All molecular modelling performed using Mercury CSD 3.7.
CCDC 970189 (KTZ–OA) and 1501152 (CFX–MA)† contain the
crystallographic data for reference in this paper.
2.10 Dissolution studies
The dissolution studies were conducted using a USP method
(Varian 705 DS dissolution paddle apparatus; Varian Inc.,
North Carolina, US). For KTZ, acetate buffer pH 4.4 was made
by using glacial acetic acid and anhydrous sodium trihydrate.
For CFX, acidic media pH 1.2 and phosphate buffer pH 6.8
was used as the dissolution medium. 100 mg of bulk KTZ/CFX
and an equivalent amount of extruded and grinded powder
was placed in the apparatus. The total buffer used in each
apparatus was 900 ml and the temperature of the buffer was
set 37.5 ± 1 °C with a rotation speed of 100 rpm. 5 ml of
sample was collected from the apparatus after 15 min and
immediately replaced by 5 ml of buffer. This process was
repeated at the following time intervals: 30, 60, 90, 120 and
180 min. All samples collected at different time intervals were
taken immediately for HPLC analysis.
2.11 High-performance liquid chromatography
The amount of KTZ and CFX present in the collected samples
was determined by HPLC analysis. A fresh mobile phase con-
sisting of methanol: water: triethylamine (TEA) 80 : 20 : 0.02%
(v/v) was used and the flow rate of the mobile phase was
1 ml min−1. The injection volume of the sample was fixed at
20 μl and the eluent was monitored with a UV detector set at a
wavelength of 240 nm. The pressure bar of the column was
110 bar and the retention time for KTZ peak was ∼3.0 min.
The results were integrated by using Chemstation® software.
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For CFX detection, the mobile phase was 2% acetic acid: aceto-
nitrile (70 : 30; v/v). The wavelength of the detector was set at
264 nm and pressure bar of the column was 137 bars. The
retention time was about 4.73 min. All other parameters were
the same as for KTZ detection, including flow rate.
3. Results and discussion
During the extrusion, both drug-former blends were subjected
to thermal and mechanical processing within the heated
barrel using specific screw configurations. In addition, the pro-
cessing parameters such as feed rate, screw speed, and
thermal profile were optimised to achieve a complete trans-
formation of the raw materials to pharmaceutical salts, with
CFX–MA F4 showing to be the most optimal processing
method. CFX–MA F1 produced sludge, as the screw tempera-
tures were too high and the components degraded, while CFX–
MA F2 and F3 were shown to produce inferior quality salts
after PXRD evaluation (Table 1). Investigation of the extruded
powder revealed some blackened material in the batch, indi-
cating that the screw temperatures were still too high, leading
to the degradation of some of the malic acid in the batch
before it could salify.21 Due to the different melting tempera-
tures of the starting materials the processing temperature
profile of KTZ–OA was found between the melting points of
the reactants (50°, 75°, 110°, 175°, 185°, 185°, 185° and
185 °C). In contrast, the CFX–MA processing temperatures
were approximately 10 °C below the melting point of MA (50°,
80°, 100°, 100°, 130°, 130°, 130° and 100 °C). This is not
unusual for salt extrusion processing and it is related to the
drug-former miscibility. Table 1 shows the thermal profiles
used for the optimization of CFX–MA salts which shows that
lower processing temperatures resulted in better salt crystalli-
nity. It is evident that the processing temperature profile plays
a key role in the salt formation and it is important to identify
the suitable settings for the synthesis of high-quality salts. At
the end of the ssTME process, the formed salts were collected.
The CFX–MA and KTZ–OA salts both presented a granular
morphology after ssTME processing. The crystal structure of
KTZ–OA can be seen in Fig. 1A which shows a single ketocona-
zole and oxalic acid molecule in one asymmetric unit. This
compound is classed as an oxalate salt because proton transfer
takes place between the hydroxyl O-atom of the OA molecule
and the imidazole N-atom of the KTZ molecule, resulting in
then KTZ and OA moieties being bonded via a N (1)–H(1A)⋯O
(4A) hydrogen bond. Strong dimers are formed between the OA
moieties via O(1A)–H(1AA)⋯O(3A) bidentate intermolecular
hydrogen bonds. The imidazole ring of the KTZ molecule is
linked to the contiguous OA dimers through a C–H⋯O hydro-
gen bond with the carbonyl O-atom of the OA moiety. The
crystal packing arrangement of KTZ–OA salts can be seen in
Fig. 1B, showcasing the stacking interactions between KTZ’s
imidazole rings. The 5- and 6-member rings adopt an envelope
and chair conformation respectively.4a The CFX–MA salt forms
when one ciprofloxacin cation and one maleate anion crystal-
lize within the monoclinic P21/n space group. The CFX and
MA ions are joined via two charged assisted N+–HO hydrogen
bonds which form a closed tetrameric ring, while weaker van
der Waals interactions occur between the neighbouring units20
(Fig. 2A). Pi stacking occurs between the parallel quinolone
moieties of the ciprofloxacin molecules (Fig. 2B).9 Fig. 3 shows
Fig. 1 (A) Hydrogen bonds between OA dimers and imidazole ring of
the KTZ moiety (B) crystal packing projections for KTZ–OA salt. Other
hydrogen and van der Waals bonds have been omitted for clarity.
Fig. 2 (A) Interaction between the CFX and MA molecules via duel N+–
HO hydrogen bonds (B) crystal packing projections for CFX–MA salts.
Other hydrogen and van der Waals bonds have been omitted for clarity.
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SEM images of the KTZ–OA, and CFX–MA salts which appear
to be aggregates of smaller particles with spherical-shaped
morphology. In comparison the bulk materials particle size
were slightly smaller and showed no apparent aggregates to be
present. The agglomeration of the extrudates is attributed to
the partial melting of the raw materials and the molecular
interactions of the drug-former pairs during processing.
The graph in Fig. 4 illustrates the particle size distribution,
showing a significant decrease of the small particle size frac-
tions (from 5–40 μm), in the extruded salts compare to the
bulk drug substance suggesting a change of the size during
extrusion processing. The rest of the particle sizes are distribu-
ted between 40–300 μm, with negligible amounts above
500 μm. By comparing the particle size of bulk KTZ and CFX
to that of the feeding materials (ESI†) it is evident that the
thermomechanical processing reduced the fines and increased
particle agglomeration. The LAG processed salts presented par-
ticle size distributions similar to the ssTME produced batch.
Although SEM results show the presence of big aggregates in
the extruded materials which can be attributed to the partial
melting of the raw materials and the molecular interactions of
the drug-former pairs during processing. The partial melting
of the raw materials facilitates the formation of salts during
the extrusion process and as salts were formed, these aggre-
gates don’t affect the rate of dissolution, as they quickly deag-
glomerate once added into the dissolution medium. A similar
morphological effect was observed in the salt prepared by LAG,
which was the effect of milling for a longer time and use of
small amount of solvents which worked as a catalyst for the
salt formation in grinding process. One outlier here was the
CFX–MA amounts processed via LAG which produced aggre-
gates of a much larger particle size distribution compared the
ssTME salts. Though morphologically, as observed through
SEM, the CFX–MA salts are near identical, whether produced
by LAG or ssTME, it was observed during dissolution that the
LAG produced CFX–MA salts were slower to disintegrate, par-
tially contributing to their slower dissolution rate compared to
the ssTME produced salts. It should be further noted that the
CFX–MA salts showed great variation in particle size distri-
bution depending on how they were processed. As Fig. 4 shows
the ssTME salts had almost double the number of particles
<10 μm when compared to LAG produced salts, while the LAG
prepared sample had almost double the number of particles
>100 μm in contrast to the ssTME salts. In contrast the KTZ–
OA salts tended to be much similar in particle size distri-
bution, though there were noticeably more particles >100 μm
in the ssTME salts. This is likely due to the shorter formation
time seen for CFX–MA during ssTME processing, providing a
reduced chance for aggregate formation.13 The SEM images for
bulk and LAG processed materials can be found in the ESI.†
Fig. 4 Particle size distribution of bulk materials and salts synthesised
by ssTME and LAG.
Fig. 3 SEM images of (A) KTZ–OA and (B) CFX–MA synthesised by
ssTME.
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Further characterisation involved DSC and PXRD analysis to
evaluate the quality of the ssTME salts. The bulk KTZ and CFX
showed melting endotherms at 151.19 °C and 270.0 °C respect-
ively. For the CFX–MA physical mixture the low endothermic
peaks at 114.77 °C and 205.77 °C were attributed to the eutec-
tic and melting point of the salt respectively. The analysis of
KTZ–OA physical mixture indicates the eutectic melt occurring
at 140.9 °C. The thermograms of KTZ–OA, and CFX–MA in
Fig. 5, presented a single endothermic peak at 193.26 °C and
219.86 °C respectively which are completely different from
those of the bulk materials. The presence of a single melting
endotherm indicates the complete conversion of the drug-
former pairs, with the absence of any residual bulk constitu-
ents, suggesting the formation of a new entity.
It is also evident that due to the excellent mixing, ssTME
processing facilitated strong interactions between the func-
tional groups of the reactants. The DSC analysis of the LAG
synthesised salts showed similar melting endotherms at
195.37 °C and 222.92 °C but at slightly higher temperatures.
The melting endotherm of KTZ–OA appeared at higher temp-
eratures of those of the bulk materials as a result of high
packing efficiency (high density and packing index) caused by
stronger ionic bonds in the salt. From Fig. 5 is evident that
ssTME synthesised salts were of similar quality to LAG proces-
sing. The PXRD patterns of KTZ–OA, and CFX–MA salts are
shown in Fig. 6 which confirm the synthesis of the salts with
intensity peaks at completely different 2theta values of the
starting materials. For the KTZ–OA salt intensity peaks
appeared at 8.75°, 10.81°, 11.95°, 13.27°, 17.72°, 18.5°, 19.89°,
20.42°, and 28.14° 2theta values while for CFX–MA salt at
10.42°, 11.25°, 13.43°, 14.65°, 17.21°, 20.37°, 24.74° and 27°
2theta values.
The KTZ–OA diffraction patterns compared to those
obtained by Martin et al. were found to be in good
agreement.4a,22 Rietveld refinements were conducted using
TOPAS V4.2 to validate the crystallinity of the extruded salts
and compare the structure of the salts produced in this study
to simulated patterns taken from the Cambridge structural
database (CSD), to estimate the percentage of the batch which
formed into a salt, whilst identifying any remaining bulk con-
stituents or contamination. Consensus regarding Rietveld
refinements is that if the weighted profile R-factor (Rwp) is
within 3× the expected R factor (Rexp), the fitting can be con-
sidered accurate.23 Here, each Rietveld fitting is within this
limit, with no fitting receiving goodness of fit (GoF) above 3.
Furthermore, the model of the observed and calculated
pattern is chemically plausible, so the standard of the fittings
done in this work can be considered of good quality. As can be
seen in Fig. 6, the measured pattern for the KTZ–OA salts
closely match the simulated pattern with minimal spikes in
the difference plot, indicating a close match between the salts
produced in this work and the CSD reference structure. This
confirms that the extruded salt is completely crystalline with
no unprocessed material present. All peaks from the KTZ–OA
Fig. 5 DSC thermograms of bulk KTZ, CFX and synthesised KTZ–OA,
CFX–MA salt.
Fig. 6 PXRD diffractograms of the bulk constituents, the KTZ–OA (top)
salts and the CFX–MA (bottom) salts processed by ssTME and LAG.
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sample match that of the simulated structure indicating pure
salt formation, with a GoF value of 1.85 suggesting the fitting
is of excellent quality. Similarly, the newly obtained diffraction
patterns of the extruded CFX–MA were compared with reported
data from the CSD. Surov et al., previously reported three poly-
morphic forms CFX–MA and one hydrate with the stability of
the three polymorphs being in the following descending order
form I > form II > form III.9 Both the extruded and LAG pro-
duced CFX–MA salts were fitted to reference patterns of the
salt from all three polymorphs to assess the physical form. The
salts processed via ssTME show complete conversion into
form II, indicating pure salt formation has taken place. This
matches the LAG produced salts, which also underwent full
conversion into form II. This shows complete salification into
a stable polymorph form is possible with ssTME.
Off-line sample analysis, from different extrusion zones,
revealed that the salt formation was initiated in conveying
zone 1 and completed in zone 3. It is evident that the configur-
ation of mixing elements at 60 and 90° angles played a signifi-
cant role in the salt formation. Additional extrusion studies
involved investigating the transformation pathway of the drug-
former pairs along the extrusion barrels.
As shown in Fig. 7 the transformation pathways vary upon
the drug-former pair. It is evident that, although the same
screw configuration was used in both cases, KTZ–OA was
almost completely converted to salt at 98.3% in the first knead-
ing zone. In contrast, CFX–MA was gradually transformed
across the process, being 71.8% complete after kneading zone
1, 90.4% complete after kneading zone 2 and 98.65% after
kneading zone 3, being fully transformed after collection at
the discharge zone. It is usually accepted that for stable salt
formation there should be a minimum difference of about 3
units between the pKa values of the salt forming groups.
Although, for both cases, KTZ–OA and CFX–MA, pKa difference
between salt forming groups were more than 3, KTZ–OA
demonstrated a faster transformation to the final salt form
compared to CFX–MA. This could be attributed to the robust
dimer forming ability of OA molecules with the imidazole
rings of the KTZ molecules. This salt paring has more readily
available donor and acceptor sites on the molecule surface to
form these charged dimers with less energy required than
seen with the CFX–MA pair. Therefore, it is likely the heat
applied during the first conveying stage in extrusion provided
the necessary energy required to start the formation of bonds
between the ionized ketoconazole and oxalate moieties. Due to
this relative ease in bonding, by the time the KTZ–OA mixture
had passed the first kneading zone, salification was mostly
complete. Conversely, the CFX–MA pairs required greater
energy to promote salification, which occurred later in the
extrusion process after being exposed to the high-shear mixing
in the first and second kneading zones. Similar to cocrystals,
the mechanism of action for salification is through eutectic
formation.12,16,20 Due to the elevated temperature of the extru-
der barrel weakening bonds within the bulk materials, and
through dispersive and distributive mixing occurring in the
kneading zones, causing particle size reduction and homo-
geneous spatial distribution between the two materials within
the extruder barrel, a eutectic melt occurs within the extruder
barrel. The elevated temperatures and pressures inside the
extruder barrel, expediates the dissolution of one constituent
in the melt of the other, without reaching the materials
melting points and without the presence of a solvent catalyst.
Kinetic energy applied through the high shear kneading,
induces viscous dissipation, further heating the mixture and
thus contributing to the eutectic event. That ssTME can
induce the dissipation process is a contributing factor in how
salification is possible at relatively low temperatures, in the
absence of any solvent. As one material dissolves into the
other, the eutectic melt experiences supersaturation, which
results in the formation of the new crystal form.8,13,16d The
comparison of IR spectra of bulk materials with synthesised
salt was studied to validate the proton transfer between the
salt former and the API. KTZ showed characteristic broad NH-
stretch peak at 3102 cm−1. The peak at 1644 cm−1 was
observed due to carbonyl CvO stretch of KTZ (Fig. 8).24
Salt former OA has two COOH groups. The –C (vO) OH
group is characterised by the OH stretch, the CvO stretch,
C–O stretch, OH in-plane deformation and the OH out-of-
plane deformation modes. An O–H group of oxalic acid is
present in the region 3200–2700 cm−1, whilst the intense peak
at 1670 cm−1 is due to CvO stretching and the C–O stretching
Fig. 7 Transformation kinetics of CFX–MA (red) and KTZ–OA (green)
salts in the extrusion segments.
Fig. 8 FTIR spectra of bulk KTA, OA, KTZ–OA physical mixture and
KTZ–OA salt.
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of the carboxylic acid is identified at 1154 cm−1 in the IR spec-
trum.25 In the KTZ OA salt, the CvO group stretching of KTZ
shift to 1624 cm−1, whilst a new peak can be observed at
1748 cm−1. The presence of shifting in the vibrational frequen-
cies of KTZ and OA indicated the formation of a supramolecu-
lar hetero synthon. The loss of a broad band OH group indi-
cated the formation of hydrogen bond in KTZ OA salt
crystals.26
CFX showed a characteristic absorption peak at 3040 cm−1
which can be assigned to C–H olefinic and aromatic chains,
with 1614 cm−1 corresponding to keto (CvO) group. The car-
boxylic group CvOOH didn’t appear in the IR spectra as CFX
is a zwitterion. The CvOOH group is present in CFX–MA salt
at 1728 cm−1 indicating that the zwitterionic nature of the CFX
was reverted by proton transfer from the MA (Fig. 9).27
MA has an asymmetric carboxylate anion peak at 1564 cm−1
and symmetric carboxylate anion at 1430 cm−1. Analysis
revealed a peak shift “N–H” stretching frequency at 3168 cm−1.
This is due to hydrogen bonding between the CFX and MA
molecules. The broad IR absorption frequencies
2509–2535 cm−1 indicated the protonation of the piperazinyl
ring N atom (NH2+). Moreover, the appearance of two charac-
teristic carboxylate IR absorption vibrations at 1486 cm−1 and
1436 cm−1, due to asymmetric and symmetric O–C–O stretch
respectively, confirmed the proton transfer from the –COOH
group in MA. The “CvO” stretching frequency for MA is
1706 cm−1 whereas it is 1728 cm−1 for CFX MA salt.27 This cor-
responded to the dimer formation of MA molecules within the
crystal packing of salt. The evidence of proton transfer
between the two salt formers, in both instances, indicates the
formation of salts and not the cocrystal forms of these drugs,
as proton transfer between an acidic substance to a more basic
one does not take place in cocrystallisation in systems where
the ΔpKa difference is greater than 4.28
As has been exemplified in numerous studies, in instances
where the pKa difference between a cocrystallising or salt
forming acid and base is greater than 3 (ΔpKa =
pKa[protonated base] − pKa[acid] > 3), salification is almost
always expected. Conversely in cases where the pKa difference
≤1 then cocrystallisation is always afforded, with any system
falling between that leading to less predictable outcomes.28 In
a 2012 study, analysing over 6000 systems Cruz-Cabeza found
that ionized acid–base complexes are seen exclusively for
systems with ΔpKa > 4 and in 80% of cases with ΔpKa > 3.29 In
the case of KTZ–OA, in which is protonated through the imid-
azole ring of KTZ, there is a pKa difference of 4.95, almost
guaranteeing salt formation. This combined with the fact that
the thermal profile and diffraction pattern reported herein, far
more closely resemble the reported values to KTZ–OA salts
than KTZ–OA cocrystals confirm that the pure salt was formed
through ssTME.30 In the case of CFX–MA, as showed through
the FTIR analysis, the bonding occurs through the protonation
of the N atom on the piperazinyl ring, which has a pKa of
8.74.31 The proton is donated from the MA molecule (pKa =
3.51), giving a pKa Difference of 5.23, strongly indicating
cocrystallisation is not possible. Combined with this, the fact
that Rietveld analysis indicated a 100% match with CFX–MA
salt reference data, and the fact no cocrystal form of CFX and
MA has been reported, it can be confidently stated that the
pure salt of CFX–MAwas formed.
The solubility of the ssTME synthesised salts were assessed
via in vitro dissolution testing (Fig. 10). The extruded salts
were tested alongside their LAG produced counterparts, over a
two-hour period to observe any improvement in drug release.
The ssTME extruded salt showed a significantly more rapid
release rate than the poorly water soluble KTZ. After
15 minutes, over 70% of the ssTME produced salt had been
released into the dissolution medium, compared to the bulk
KTZ which displayed only 28% release of drug over in the
same time period. The ssTME produced salts reached 81%
drug release after 30 minutes, before it plateaued. The bulk
KTZ did not catch up for 120 minutes at which point it pla-
teaued at 74%. Salts prepared by LAG displayed slightly less
overall drug release compared to that of the extruded salt,
though they shared similar release rates. KTZ is known to
easily dissolve in acidic conditions but shows worse solubility
the closer the medium is to neutral/basic conditions.32 As
such, dissolution testing was not conducted at 1.2 pH con-
ditions, but at 4.4 pH. The results in this study show that salt
versions of KTZ can achieve greater dissolution in less basic
conditions than the bulk substance. The dissolution profiles
of bulk CFX and the LAG prepared and ssTME synthesised
CFX–MA salts show similar findings. The extruded CFX–MA
salt showed enhanced drug release over time compared to the
bulk CFX at pH 6.8. The salt prepared by LAG showed better
release compared to bulk CFX as well, but lesser to extruded
salt. Interestingly, at pH 1.2, the release profile is different
compared to pH 6.8, where bulk CFX showed more drug
release than the CFX maleate salt prepared by both grinding
and extrusion process (ESI†) which is due to the protonation
of the piperazine ring in the acidic medium. The same behav-
iour for the dissolution profile of CFX was reported previously
by Surov et al. and Reddy et al.33 It should also be noted that
the CFX–MA salts showed greater variation in particle size,
dependent on the processing method. The LAG produced salts
Fig. 9 FTIR spectra of bulk CFX, MA, CFX–MA physical mixture and
CFX–MA salt.
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showed a far greater particle size distribution when compared
to the ssTME samples. This effect can be seen in the dis-
solution, contributing to the increased solubility the seen in
the ssTME salts, while the larger LAG produced salts display a
slower and reduced dissolution rate. Meanwhile the KTZ–OA
salts displayed similar particle sizes across the two processing
methods, which also correlates with the solubility profiles of
the two methods, as there is less difference between the dis-
solution of the two KTZ–OA salts. It must be noted, however,
that the media pH is still the much greater factor on the solu-
bility of the CFX–MA salt, as with this large difference in drug
release and dissolution time has been closed in the samples
dissolved at 1.2 pH. Here, the dissolution rates are more
similar, though the particle size effect can still be observed, as
there still exists a slight increase in the CFX drug release in the
smaller ssTME produced particles.
4. Conclusions
In conclusion, ssTME processing has been shown as a continu-
ous, solvent-free process for the formation of two high purity
pharmaceutical salts. ssTME overcomes previously reported
issues with pharmaceutical salt production, being both a con-
tinuous, scaleable process capable of excellent process control,
reproducibility and high yield production, whilst also negating
the use of solvents and being more cost-effective due to the
smaller number of process steps. This approach opens up new
avenues for the synthesis of new drug products, providing a
greener approach to the conventional solvent-mediated pro-
cess’s for pharmaceutical salt formation.
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